NEOVACS' product pipeline is distinguished by its breadth and breakthrough potential. It is principally focused on unmet needs in the treatment of autoimmune and inflammatory diseases. We are building high-value drug discovery and development programs around well-validated cytokine targets. Each product candidate has received significant public funding support.

The Company has a broad patent estate protecting its platform technology and product candidates, providing coverage out to at least 2023. The Company has retained all rights to its product candidates and technologies.